Therapeutic Response

EGFR activating variants status confers therapeutic sensitivity to Erlotinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Erlotinib Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.
Erlotinib Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for switch maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy.
Tarceva (erlotinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.
Tarceva (erlotinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatemnt of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.